ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Foldax Announces Successful First Human Use of Tria Biopolymer Mitral Heart Valve
Friday, June 4, 2021
Submitted by
Source
Source Name: Foldax news and events
On May 25, 2021, Dr. David Heimansohn successfully performed the first surgical implantation of biopolymer Tria™ heart valve in a patient with mitral valve disease at Ascension St. Vincent Hospital, Indianapolis, IN.
Foldax’s Tria valve is fabricated with a polymeric, silicone-rich polyurethane material intended to resist calcification, improve valve durability, and, most importantly, avoid the need for lifelong anticoagulation.
Printer-friendlyShare
Tags
- Transapical TAVR
- Mitral Valve
- valve
- Catheter-Based Treatments
- TAVR (TAVI)
- Transcatheter Mitral Intervention
- Cardiac
- Minimally Invasive
- Transcatheter
- Valve disease
- Aortic valve disease
- Mitral valve disease
- Tricuspid valve disease
- Aortic valve disease (congenital)
- Mitral valve disease (congenital)
- Medical technology
- Basic science